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This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. worrying microbiological characteristic to emerge from studies to date is the relative antibiotic resistance of this organism, where there is usually a high degree of antibiotic resistance to several classes of antibiotics. [5] Therefore, it was the aim of the current study to explore the potential antimycobacterial activity of veterinary antibiotics, which are used in veterinary medicine. and spectinomycin (10 µg) (aminocyclitol) [ Figure 1 ]. All plates were incubated aerobically at 37°C for 5 days, before reading. Antibiotic susceptibility was reported as resistant (R), with bacterial growth to the edge of the antibiotic disk or sensitive (S), with a zone of inhibition of at least 5-mm radius.
Methods

results
M. abscessus isolates were sensitive (100%) to apramycin and framycetin but resistant (100%) to cefovecin, ceftiofur, lincomycin, pirlimycin, and spectinomycin.
dIscussIon
This study demonstrated antimycobacterial activity of two antibiotics, commonly used in veterinary medicine, namely, apramycin and framycetin. All M. abscessus isolates tested were sensitive to these antibiotics. All other antibiotics examined from the cephalosporin, lincosamide, or aminocyclitol classes did not show any antimycobacterial activity against any of the isolates tested. Interestingly, there was no activity with streptomycin, which is an aminocyclitol antibiotic, which is closely related to the aminoglycosides.
Apramycin is currently licensed in the UK by the Veterinary Medicines Directorate for pigs, cattle, rabbits, and chickens, either as (i) a premix for medicated feedstuff (200 g/kg, 100,000 IU/g, 100 g/kg) or (ii) a soluble powder for oral solution. The indications for usage include (a) the treatment and control of bacterial enteritis in young pigs caused by Escherichia coli and other apramycin-sensitive organisms, (b) the treatment of bacterial enteritis associated with organisms susceptible to apramycin in pigs, colibacillosis, and salmonellosis in calves E. coli septicemia in young chickens, and (c) the treatment in pigs and metaphylaxis of bacterial enteritis caused by Figure 1 : Veterinary antibiotics employed in study microorganisms susceptible to apramycin such as E. coli and for the reduction in mortality in rabbits and clinical signs related to epizootic enterocolitis due to E. coli (http://www.vmd.defra. gov.uk/ProductInformationDatabase/Default.aspx). Apramycin has been shown previously to be efficacious in the treatment of Mycobacterium tuberculosis in a murine infection model, with superior kill kinetics compared to the human aminoglycoside and amikacin. [6] In addition, it has been reported as being less ototoxic than amikacin, which would make a potentially attractive alternative, especially when used continuously.
Likewise, framycetin is also an aminoglycoside antibiotic, which has indications in veterinary medicine, for cats, dogs, and cattle, for topical, intermammary, and im treatment of (i) otitis externa including the ear mite, Otodectes cynotis, infestation dogs, and cats, (ii) as an adjunct to intramammary therapy in the treatment of acute bacterial mastitis with systemic involvement, caused by organisms sensitive to framycetin in dairy cows. In vitro, framycetin has shown activity against E. coli, Staphylococcus aureus, Arcanobacterium pyogenes, and Klebsiella spp. and (iii) for treatment of subclinical mastitis at drying off and the prevention of new bacterial infections of the udder during the dry period in dairy cows, caused by bacteria susceptible to penicillin and framycetin.
To date, there have been no reports on antimycobacterial activity of framycetin against the mycobacteria.
At the present, as there are no interpretive criteria, including EUCAST or CLSI, to help determine antibiotic breakpoints for these two aminoglycoside antibiotics and M. abscessus, fundamental/basic science studies and pharmacokinetic/pharmacodynamics studies are now required to estimate the potential value of such antibiotics entering human medicine for nebulized or intravenous treatment of M. abscessus chronic infection and aiding their assessment by the human medicine drug regulators, including the Food and Drug Administration and the European Medicines Agency.
Given the increasing burden of antimicrobial resistance globally, particularly with the mycobacteria, it is, therefore, important to explore all potential sources of antibacterial activity and their potential route to successful registration and employment, to strengthen society's arsenal of availability antibiotics.
conclusIon
This study has identified that the veterinary aminoglycosides, apramycin and framycetin, have in vitro activity against multi-resistant clinical isolates of M. abscessus. Further studies should now compare the activity of these antibiotics against amikacin, the human aminoglycoside, advocated in the treatment of disease in CF patients, to determine if these novel antibiotics have a future role for the development in human medicine.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
references
